[1] Naqvi AAT, Mohammad T, Hasan GM, Hassan MI. Advancements in Docking and Molecular Dynamics Simulations Towards Ligand-receptor Interactions and Structure-function Relationships. Curr Top Med Chem, 2018; 18: 1755-1768.
[2] Jafari R, Sadeghi M, Mirzaie M. Investigating the importance of Delaunay-based definition of atomic interactions in scoring of protein-protein docking results. J Mol Graph Model, 2016; 66: 108-14.
[3] MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FT, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B, 1998; 102: 3586-616.
[4] Hawkins PC, Skillman AG, Nicholls A. Comparison of shape-matching and docking as virtual screening tools. J Med Chem, 2007; 50: 74-82.
[5] Pozzan A. Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr Pharm Des, 2006; 12: 2099-110.
[6] Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem, 2006; 49: 5851-5.
[7] Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect Dis, 2015; 1: 317-26.
[8] Mallipeddi PL, Kumar G, White SW, Webb TR. Recent advances in computer-aided drug design as applied to anti-influenza drug discovery. Curr Top Med Chem, 2014; 14: 1875-89.
[9] Savarino A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J Clin Virol, 2005; 34: 170-8.
[10] Jo S, Kim H, Kim S, Shin DH, Kim MS. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des, 2019; 94: 2023-2030.
[11] Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect, 2020; 9: 601-604.
[12] Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol Inform, 2020.
[13] Ekins S, Mottin M, Ramos P, Sousa BKP, Neves BJ, Foil DH, Zorn KM, Braga RC, Coffee M, Southan C, Puhl AC, Andrade CH. Déjà vu: Stimulating open drug discovery for SARS-CoV-2. Drug Discov Today, 2020.
[14] Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model, 2012; 52: 1757-68.
[15] Liu X, Zhang B, Jin Z, Yang H, Rao Z. The crystal structure of COVID-19 main protease in complex with an inhibitor N3. Protein DataBank: New York, NY, USA, 2020.
[16] Daina A, Michielin O, Zoete V. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model, 2014; 54: 3284-301.
[17] Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem, 2016; 11: 1117-21.
[18] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep, 2017; 7: 42717.
[19] Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive molecules. Bioinformatics, 2013; 29: 3073-9.
[20] Cramer G, Ford R, Hall R. Estimation of toxic hazard—a decision tree approach. Food and cosmetics toxicology, 1976; 16: 255-276.
[21] Munro IC, Ford RA, Kennepohl E, Sprenger JG. Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern. Food Chem Toxicol, 1996; 34: 829-67.
[22] Patlewicz G, Jeliazkova N, Safford RJ, Worth AP, Aleksiev B. An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. SAR QSAR Environ Res, 2008; 19: 495-524.
[23] Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res, 2019; 47: W357-w364.
[24] Çiçek İ, Tunç T, Ogutcu H, Abdurrahmanoglu S, Günel A, Demirel N. Synthesis and Antibacterial Activity of New Chiral Aminoalcohol and Benzimidazole Hybrids. ChemistrySelect, 2020; 5: 4650-4654.
[25] Lipinski CA. Avoiding investment in doomed drugs. Curr Drug Discov, 2001; 1: 17-19.
[26] Hsieh M, Conti M. G-protein-coupled receptor signaling and the EGF network in endocrine systems. Trends Endocrinol Metab, 2005; 16: 320-6.
[27] Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol, 2004; 5: 248.
[28] Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. Eur J Pharm Sci, 2016; 93: 244-52.
[29] WHO. Laboratory biosafety manual. Geneva: World Health Organization 2004.
[30] WHO. Laboratory testing strategy recommendations for COVID-19: interim guidance, 22 March 2020. In: ed.^eds. World Health Organization, 2020.
[31] Trivella JP, Gutierrez J, Martin P. Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C. Expert Opin Pharmacother, 2015; 16: 617-24.
[32] Sayin M, Gurgen GS, Sayin SS, Guvenc G, Yuceer N. Does the Anti-Migraine Drug Rizatriptan Affect Early Neural Tube Development in Chick Embryos? Turk Neurosurg, 2019; 29: 106-109.
[33] Fard JK, Hamzeiy H, Sattari M, Eftekhari A, Ahmadian E, Eghbal MA. Triazole rizatriptan Induces Liver Toxicity through Lysosomal/Mitochondrial Dysfunction. Drug Res (Stuttg), 2016; 66: 470-478.
[34] Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S, Woerle HJ, Dugi K. Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. Clin Pharmacol Drug Dev, 2013; 2: 152-61.
[35] Kohler S, Salsali A, Hantel S, Kaspers S, Woerle HJ, Kim G, Broedl UC. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Clin Ther, 2016; 38: 1299-1313.
[36] Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy, 2013; 33: 984-99.
[37] Patel P, Louie S. Drug Interactions in HIV: Protease and Integrase Inhibitors. In: ed.^eds., Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Springer, 2018; pp. 255-295.
[38] Shen J, Serby M, Reed A, Lee AJ, Menon R, Zhang X, Marsh K, Wan X, Kavetskaia O, Fischer V. Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans. Drug Metab Dispos, 2016; 44: 1139-47.
[39] Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc, 2020; 23: e25489.
[40] Ke YY, Peng TT, Yeh TK, Huang WZ, Chang SE, Wu SH, Hung HC, Hsu TA, Lee SJ, Song JS, Lin WH, Chiang TJ, Lin JH, Sytwu HK, Chen CT. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed J, 2020.
[41] Jimeno C, Anonuevo-Cruz MC, Uy AB, Bacena AO, Francisco MD, Tiglao-Gica AL, Bruno R, Corpuz DG. UP Philippine General Hospital Division of Endocrinology, Diabetes & Metabolism Consensus Recommendations for In-Patient Management of Diabetes Mellitus among Persons with COVID-19. Journal of the ASEAN Federation of Endocrine Societies, 2020; 35.
[42] Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, Radenkovic D, Montecucco F, Sahebkar A. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci, 2020; 16: 490-496.
[43] Dashti-Khavidaki S, Khalili H. Considerations for Statin Therapy in Patients with COVID-19. Pharmacotherapy, 2020; 40: 484-486.
[44] El Kassas M, Elbaz T, Hafez E, Wifi MN, Esmat G. Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opin Drug Discov, 2017; 12: 635-642.
[45] Bidell MR, McLaughlin M, Faragon J, Morse C, Patel N. Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infect Dis Ther, 2016; 5: 299-312.
[46] Dimmock NJ, Easton AJ, Leppard KN. Introduction to modern virology. John Wiley & Sons 2016.
Pathobiology Reserach